Dementia with Lewy Bodies (DLB)
Phase 2b RewindD-LB Study
The U.S. National Institute on Aging (NIA), part of the National Institutes of Health (NIH), has awarded $21M for a clinical trial in people with Dementia with Lewy bodies (DLB). EIP Pharma’s investigational drug neflamapimod is designed to target a protein in the brain that is activated by stressors, including brain changes associated with the development of dementia. This phase 2b study will be instrumental in fully understanding whether neflamapimod has the potential to become an important treatment for patients with DLB.
Dementia with Lewy Bodies Consortium (DLBC) Study
This project establishes a group of centers dedicated to the study of DLB, the DLB consortium (DLBC). DLBC will enroll a large number of participants within the United States; perform systematic assessments (compatible with other AD and PD programs); collect biofluids, imaging data, and ultimately autopsy results; and bring together experts in DLB to perform collaborative research. The ultimate goal of DLBC is to allow for the discovery of a biomarker for DLB to improve the diagnosis, care, and treatment of patients with this disease.
DLBC is currently recruiting participants with Lewy Body dementia, Lewy body dementia/MCI (mild cognitive impairment) or Parkinson’s disease dementia that will be followed over a period of five years with detailed clinical information, collection of biospecimens, and imaging data. Participants will be asked to complete assessments to examine cognitive skills (e.g. memory, language), mood and sleeping behaviors. A study partner is required for enrollment into DLBC.
For Dementia with Lewy Bodies Study interest, please complete the form below and a CCBH representative will contact you or call us at 561-869-6828.